- Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab.
- Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have little effect on non-ApoE4 carriers and only a modest effect on ApoE4 carriers.
- Targeting points in the pathway that follow receptor activation may lead to initial improvements in cognition that are not likely to be sustained.
- Drugs and natural products that limit the formation of peroxynitrite, scavenge peroxynitrite, and partially reverse peroxynitrite-mediated damage may stabilize or substantially slow down the progression of Alzheimer's disease.
- Anavex 2-73 is the only drug to date that significantly reduces cognitive loss and stabilizes activities of daily living in Alzheimer's disease at almost three years.
For further details see:
Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73